Antidepressant Recalled

Teva Pharmaceuticals is pulling more than a million 30-count bottles of fluoxetine tablets USP, 10 mg (NDC 0093-7188-56), because the drug was out of specification for impurities during routine testing, according to the February 21, 2018, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects all lots within expiry, specifically lots 732259, 732260, 732261, 732262, 732263, 732264, 732265, 732266, 732267, 732268, 732269, 732270, 732272, 732273, 732274, 732275, 732276, 732277, 732278, 732280, 732281, 732282, 732283, 732284, 732285, 732286, 732287, 732288, 732289, 732293, 732294, 732296, 732297, 732295, 732298, 732299, 732300, and 732301. The bottles were distributed throughout the United States.

Teva Pharmaceuticals voluntarily initiated the recall February 5, 2018. At press time, the FDA had not announced a recall classification.

Fluoxetine is a prescription selective serotonin reuptake inhibitor used to treat depression, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder.

—Jolynn Tumolo

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here